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Low levels of Caspase-3 predict favourable response to
5FU-based chemotherapy in advanced colorectal
cancer: Caspase-3 inhibition as a therapeutic approach
L Flanagan1,2, M Meyer1,2, J Fay3, S Curry3, O Bacon1,4, H Duessmann1, K John5, KC Boland1, DA McNamara4, EW Kay3, H Bantel5,
H Schulze-Bergkamen6,7 and JHM Prehn*,1,2
Colorectal cancer (CRC) is one of the most common cancers in the Western world. 5-Fluorouracil (5FU)-based chemotherapy (CT)
remains the mainstay treatment of CRC in the advanced setting, and activates executioner caspases in target cells. Executioner
caspases are key proteins involved in cell disassembly during apoptosis. Activation of executioner caspases also has a role in
tissue regeneration and repopulation by stimulating signal transduction and cell proliferation in neighbouring, non-apoptotic cells
as reported recently. Tissue microarrays (TMAs) consisting of tumour tissue from 93 stage II and III colon cancer patients were
analysed by immunohistochemistry. Surprisingly, patients with low levels of active Caspase-3 had an increased disease-free
survival time. This was particularly pronounced in patients who received 5FU-based adjuvant CT. In line with this observation,
lower serum levels of active Caspase-3 were found in patients with metastasised CRC who revealed stable disease or tumour
regression compared with those with disease progression. The role of Caspase-3 in treatment responses was explored further in
primary human tumour explant cultures from fresh patient tumour tissue. Exposure of explant cultures to 5FU-based CT increased
the percentage of cells positive for active Caspase-3 and Terminal Deoxynucleotidyl Transferase dUTP Nick end Labelling (TUNEL),
but also the expression of regeneration and proliferation markers β-Catenin and Ki-67, as well as cyclooxygenase-2 (COX-2). Of
note, selective inhibition of Caspase-3 with Ac-DNLD-CHO, a selective, reversible inhibitor of Caspase-3, significantly reduced the
expression of proliferation markers as well as COX-2. Inhibition of COX-2 with aspirin or celecoxib did not affect Caspase-3 levels
but also reduced Ki-67 and β-Catenin levels, suggesting that Caspase-3 acted via COX-2 to stimulate cell proliferation and tissue
regeneration. This indicates that low levels of active Caspase-3 may represent a new predictor of CTresponsiveness, and inhibition
of Caspase-3, or antagonising downstream effectors of Caspase-3 paracrine signalling, such as COX-2 may improve patient
outcomes following CT in advanced CRC.
Cell Death and Disease (2016) 7, e2087; doi:10.1038/cddis.2016.7; published online 4 February 2016
Colorectal cancer (CRC) has the third highest incidence
rate and the fourth highest mortality rate of any cancer in
the Western world. Surgery alone, or combined with
5-Fluorouracil (5FU)-based chemotherapies, is the current
treatment option for stage II and advanced, stage III CRC. The
response rate to palliative 5FU-based treatments for meta-
static stage IV CRC is c. 40–50%, but median overall survival
(OS) remains low at c.16–19 months.
Most common chemotherapeutics lead to the induction of
apoptosis in the targeted cancer cell. Caspases are cysteine
proteases that are crucial to the morphological and biochem-
ical changes that occur during apoptosis. Caspases-3 and -7
are the main executioner caspases in the cell. Caspase-3
targets structural substrates leading to cell disassembly and
DNA fragmentation.1 Caspase-7 has similar functions and in
the absence of Caspase-3 apoptosis will still occur, albeit with
a slower kinetic.2 Despite sharing many substrates and
compensating for each other in apoptosis, there are specific
functions of Caspase-3 that cannot be replaced by Caspase-
7, as Caspase-3 acts on a wider range of substrates.3
Caspase-3 has also been shown to be involved in a number
of processes that are not directly linked to cell disassembly.
Activation of executioner caspases during apoptosis has an
important role as a negative regulator of the immune response
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by triggering the release of anti-inflammatory cytokines and
suppressing the inflammatory response.4,5 Alongside these
roles in immune suppression, executioner caspases have
a role in tissue regeneration and proliferation. Although
Caspase-3 activation causes cell death in the host cell, it
has been found to stimulate cell proliferation in neighbouring,
non-apoptotic cells. This phenomenon is important in wound
healing and tissue regeneration,6,7 but may potentially hinder
success in chemotherapy (CT) regimens. Although less
resistant cells may activate Caspase-3 and undergo apopto-
sis, these dying cells may send out signals to more resistant
cancer cells promoting proliferation and repopulation. In many
cancer types, patients with poor prognosis display highly
proliferating tumours.8,9
It has been demonstrated in amodel of head regeneration in
hydra that caspases are required for nuclear translocation of
β-catenin and Wnt signalling during regeneration, linking for
the first time caspase activation mechanistically with tissue
regeneration.10 Cyclooxygenase-2 (COX-2) activation may
link these two processes: It is known that Wnt activation in
cancer tissue and cancer stem cells is activated by
Prostaglandin E2 (PGE2), which is produced predominantly
from arachidonic acid (AA) by COX and Prostaglandine
E synthases.11 Zhao et al.12 showed that Caspase-3
generates a truncated, active form of calcium-independent
Phospholipase A2, iPLA2 (514–806). Activation of iPLA2
(514–806) generates lysophosphatide acid and arachidonic
acid, a substrate for COX-2. In a model of breast cancer,
Huang et al.13 showed an increase in PGE2 levels and cell
proliferation downstream of Caspase-3 activation upon
apoptosis induction, and that there was reduced AA release,
PGE2 production and cell proliferation in Casp3− /− cells
which could be rescued by overexpression of iPLA2
(514–806). Similar results have been reported in a model of
skin regeneration, where the authors demonstrated that
Caspase-3 was required to stimulate proliferation and
regeneration via Caspase-3-dependent iPLA2 activation,
resulting in AA synthesis and subsequent PGE2 and
Wnt/beta-catenin signalling.14
In the present study, we therefore examined Caspase-3 as a
prognostic marker in stage 2/3 as well as in metastatic CRC
patients, and further explored the role of caspase-3 as a
potential predictive biomarker for 5FU-based CT and ther-
apeutic target in CRC using primary human tumour explant
culture.
Results
Low Caspase-3 activation indicates increased disease-
free survival and better outcome for CRC patients. To
explore the association of Caspase-3 with patient outcome,
we examined tissue microarrays (TMAs) consisting of tumour
tissue from a total of 93 CRC patients. This cohort consisted
of stage II and III patients who underwent surgery followed by
observation alone (N=58), or observation alongside
5FU-based CT (N= 35). Slides were stained for both
Pro- and active Caspase-3 (Figure 1a).
Tumour areas were defined as positively stained cell
structures within the overall malignant epithelium of the
colonic crypt. Tumours were scored semi-quantitatively using
an own adaptation from Allred score technique, on a scale of
0–3 based on the extent and intensity of staining (0= no
stained cells; 1= low. Faint, partial to moderate staining in
≤20%of cells; 2=medium.Weak, partial tomoderate staining
in 420% of cells; 3=high. Strong, moderate to complete
staining in ≥70% of cells). Following the recommendations
made in the American Society of Clinical Oncology
(ASCO)–College of American Pathologists (CAP) Test
Guideline,15 a cutoff value of 1% of stained cells was used to
discriminate between positive (41%) and negative (o1%)
cases.16 Patients were allocated as having either a low or high
level of Caspase-3 and active Caspase-3 based on the
median level of Caspase-3 in all patients. Survival analysis of
the total cohort demonstrated that ProCaspase-3 levels were
not associated with survival time (Figure 1b,P=0.917;N= 93,
40 patients expressed low protein levels, of which 10 recurred,
and 53 patients expressed high levels, of which 13 recurred).
However, patients who had low levels of active Caspase-3 had
a significantly improved disease-free survival (DFS) when
compared with patients with high levels of the active protein
(Figure 1e, P=0.045; N=93, 64 patients expressed low
protein levels, of which 15 recurred, and 29 patients expressed
high levels, of which 6 recurred). When we examined active
Caspase-3 levels in the cohort of patients who received CTwe
found that again patients who had low levels of active
Caspase-3 had a significantly improved DFS in comparison
with patients with high levels of the active protein (Figure 1f,
P= 0.013; N=35, 23 patients expressed low protein levels,
with 2 experiencing recurrence, and 12 patients expressed
high levels, with 5 experiencing recurrence). In the group of
patients who did not receive CTactive Caspase-3 levels could
not stratify patients (Figure 1g, P= 0.711; N=58, 37 patients
expressed low protein levels, with 11 experiencing recurrence,
and 21 patients expressed high levels, with 3 experiencing
recurrence). Similarly, low ProCaspase-3 levels showed no
association with DFS whether the patients received CT
(Figure 1c, P=0.666; N= 35, 12 patients expressed low
protein levels, with 2 experiencing recurrence, and 23 patients
expressed high levels, with 5 experiencing recurrence) or not
(Figure 1d, P=0.193; N=58, 30 patients expressed low
protein levels, with 8 experiencing recurrence, and 28 patients
expressed high levels, with 7 experiencing recurrence). These
data suggested active Caspase-3 in tumour tissue as a
predictive marker for CRC patients receiving 5FU-based CT,
allowing for the identification of patients who are likely to
respond to therapy.
Western blot analysis performed on staurosporine-treated
human colon cancer HCT116 cells confirmed that the
ProCaspase-3 and the active Caspase-3 antibodies used
only detected the pro-enzyme and cleaved form, respectively
(Figure 1h).
To examine a potential correlation between the expression
of active caspase-3 and proliferation markers, we also
evaluated Ki-67 levels in the TMAs. Semi-quantitative analysis
of Ki-67 staining and active Caspase-3 staining on the CRC
TMAs did not reveal a significant correlation (Spearman
correlation analysis: rho=0.007, P=0.95); however, there
was a positive correlation in the CT versus untreated group
(rho=0.10, P=0.50 versus rho=  0.03, P=0.82) albeit
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none of these correlations were statistically significant.
Survival analysis demonstrated that Ki-67 levels at time of
tumour resection were not associated with length of survival
(Supplementary Figure).
Caspase-3 activity in the serum of metastatic CRC
patients is negatively associated with patient response
to therapy. To validate our findings of Caspase-3 as a
prognostic biomarker using a methodologically different
Figure 1 Low active Caspase-3 levels in patient tumours results in a significantly better disease-free survival time compared with high active Caspase-3 levels in stage 2/3
CRC patients receiving 5FU-based CT. (a) TMA sections, comprises 93 patient tumours, were stained for Pro- and active Caspase-3 and scored based on extent and intensity of
staining (scale bar= 100 μm). (b) Protein levels were correlated to patient outcome, and patients with low ProCaspase-3 (blue) did similarly to those with high ProCaspase-3
(green). (N= 93, 40 patients expressed low protein levels and 53 patients expressed high levels). (c and d) This survival pattern was observed whether patients received CT
(c; N= 35, 12 patients expressed low protein levels, with 2 experiencing recurrence, and 23 patients expressed high levels, with 5 experiencing recurrence) or not (d; N= 58, 30
patients expressed low protein levels, with 8 experiencing recurrence, and 28 patients expressed high levels, with 7 experiencing recurrence). (e) Patients with low levels of active
Caspase-3 were found to have a significantly better disease-free survival than patients with high Caspase-3 (P= 0.045; N= 93, 64 patients expressed low protein levels and 29
patients expressed high levels). (f) In the CT group, this effect was further emphasised and disease-free survival was again increased in patients with low active Caspase-3
(P= 0.013; N= 35, 23 patients expressed low protein levels, with 2 experiencing recurrence, and 12 patients expressed high levels, with 5 experiencing recurrence). (g) In the
patients who received no chemotherapy this effect on disease-free survival was lost (N= 58, 37 patients expressed low protein levels, with 11 experiencing recurrence, and 21
patients expressed high levels, with 3 experiencing recurrence). (h) Western blot analysis on HCT116 cell line, untreated and treated with STS, confirmed that the antibodies
(cleaved Caspase-3 antibody, 9661, CST and ProCaspase-3 Antibody, HPA002643, Atlas Antibodies) only detected the active (cleaved) form of Caspase-3 and the proform,
respectively. MCF7 cells were included as a negative control for specificity determination of the ProCaspase-3 antibody
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approach, we examined whether Caspase-3/-7 activity in the
serum may also correspond to response to therapy in
metastatic CRC patients. Patient cohort consisted of 30
metastatic CRC patients who received a standard CT, that is,
FOLFOX or FOLFIRI, with or without anti-EGFR /-VEGFR
antibody treatment (Table 2). Baseline levels of Caspase-3/-7
activity in serum were higher in patients who went on to have
progressive disease (PD) and a poor response to therapy
(n=7, 3082.7±1173.1 relative light units (RLU)), while those
patients who showed a response to therapy and stable
disease (SD, n=14) or partial tumour regression (PR, n=9)
displayed lower Caspase-3/-7 activity (1579.8±239.8 RLU;
Figure 2a). This effect was further emphasised following
14 days of treatment, when Caspase-3/-7 activity was
significantly (Po0.05) higher in patients with PD
(2029.3±450.0 RLU) compared with SD and PR patients
(1295.2±349.5 RLU; Figure 2b). We then calculated the
cutoff value for Caspase-3/-7 activity, which allows the
prediction of disease progression with the best compromise
sensitivity/specificity. As demonstrated by receiver operating
characteristics (ROC) analysis (Figure 2c), we identified a
cutoff value of 1076.5 RLU for Caspase-3/-7 activity in the
serum which could early (day 14 of therapy) predict PD with a
sensitivity of 86% and a specificity of 78% (area under the
curve (AUC) 0.81, 95% confidence interval (CI) 0.63–0.99).
5FU-based CT activates Caspase-3 and increases
proliferation markers in patient-derived primary human
tumour explant cultures. To investigate in more detail
whether CT-induced Caspase-3 activation may drive
proliferation, we used a novel explant technique that utilises
haemostatic gelatine dental sponges as a support, upon
which fresh patient tissue can be placed and cultured.17,18
Treatments were added to the media surrounding the sponge
and diffused through the sponge to be taken up by the tissue.
Using this model, we treated 19 fresh colon tumours taken at
surgery with 5FU-based CT (30 μg 5FU/10 μg Oxaliplatin)
alone and in combination with a specific Caspase-3 inhibitor,
Ac-DLND-CHO19 (30 μg 5FU/10 μg Oxali+200 nM Ac-DNLD-
CHO; hereafter DLND) and COX-2 inhibitors Aspirin and
Celecoxib (30 μg 5FU/10 μg Oxali+2.5 mM Aspirin and 30 μg
5FU/10 μg Oxali+50 μM Celecoxib). Tissues were then fixed,
embedded, sectioned, and stained for Pro- and active
Caspase-3 (Figure 3a). ProCaspase-3 levels were
unchanged across the treatment groups (Figure 3b); how-
ever, active Caspase-3 levels increased following 5FU-based
CT. Specific inhibition of Caspase-3 in combination with
5FU-based treatment effectively inhibited Caspase-3 activa-
tion as expected (5FU/Oxali versus 5FU/Oxali+DNLD;
P= 0.021; analysis of variance (ANOVA) and post hoc
Tukey’s test). To examine the proposed Caspase-3-
dependent proliferation pathway COX-2 inhibitors, aspirin
and celecoxib, were utilised and found to not be effective in
inhibiting Caspase-3 activation (Figure 3c). Apoptosis
induction in tumours was also verified with a Terminal
Deoxynucleotidyl Transferase dUTP Nick end Labelling
(TUNEL)-based apoptosis assay. The results mirrored the
results of Caspase-3 activation, whereby apoptosis was
induced following 5FU-based CT (Untreated versus
5FU/Oxali; P= 0.00013; ANOVA and post hoc Tukey) but
Caspase-3 inhibition reduced apoptosis (5FU/Oxali versus
5FU/Oxali+DNLD; P=0.001; ANOVA and post hoc Tukey).
COX-2 inhibition had no significant effect on apoptosis
induction (Figure 3d). These results first validate our explant
model and show that treatments reached the tissue, and
tissue responded to each treatment regime. Furthermore, the
results show that COX-2 inhibitors did not affect Caspase-3
activation and apoptosis induction.
Inhibition of Caspase-3 and COX-2 results in a reduction
in the expression of proliferation markers. Once we had
established that our primary tumour explant culture system
allowed for efficient treatment of tumour tissue, we next
examined by immunohistochemistry how our treatment
scenarios altered proliferation profiles in tumours. We
analysed COX-2, β-Catenin, and Ki-67 (Figure 4a). As
previously mentioned, COX-2 is activated in the proposed
Caspase-3-dependent proliferation pathway17 leading to
β-Catenin translocation, culminating in proliferation in
neighbouring cells. Ki-67 was also analysed due to its
Figure 2 High levels of Caspase-3/-7 activity in the serum are indicative of PD in metastasised colorectal carcinoma patients (a). In a cohort of 30 metastatic CRC patients,
Caspase-3/-7 activity levels in the serum were evaluated at baseline (before therapy) according to their treatment response following the first cycle of CT. PD (N= 7) was
associated with higher Caspase-3/-7 activity compared with SD (N= 14) and partial response (PR; N= 9). (b) Patients who displayed PD revealed significantly higher levels of
Caspase-3/-7 activity in their serum when compared with patients who displayed SD or partial tumour regression at day 14 following commencement of therapy. (c) Caspase-3/-7
activity levels in these patients could predict PD at day 14 with a sensitivity of 86% and a specificity of 78%. *Po0.05
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preferential expression in all active stages of the cell cycle.20,21
Chemotherapy caused COX-2 and β-Catenin expression to
increase (Figures 4b and c), and there was a significant
difference between levels of these proteins in untreated versus
5FU/Oxali-treated tissue (COX-2; Untreated versus 5FU/Oxali,
P=0.00017, β-Catenin; Untreated versus 5FU/Oxali,
P=0.00237; ANOVA and post hoc Tukey). Interestingly,
Caspase-3 inhibition in combination with CT (30 μg
5FU/10 μg Oxali+200 nM DNLD) significantly reduced the
expression of β-Catenin and Ki-67 when compared with CT
alone (Figures 4c and d; β-Catenin; 5FU/Oxali versus
5FU/Oxali+DNLD; P=0.001; Ki-67; 5FU/Oxali versus 5FU/
Oxali+DNLD; P=0.008; ANOVA and post hoc Tukey).
Furthermore, Caspase-3 inhibition in combination with CT
also reduced COX-2 levels (Figure 4b; COX-2; 5FU/Oxali
versus 5FU/Oxali+DNLD; P=0.000443; ANOVA and post hoc
Tukey). Chemotherapy also caused a significant increase in
PGE2 release into the media (Figure 4f, Untreated versus
5FU/Oxali; P=0.034), while specific Caspase-3 and COX-2
inhibition reduced PGE2 release (Figure 5f, 5FU/Oxali versus
5FU/Oxali+DNLD, P=0.033; 5FU/Oxali versus 5FU/Oxali
+Aspirin, P=0.021; 5FU/Oxali versus 5FU/Oxali+Celecoxib,
P=0.045; n=4–6 explants per condition; ANOVA and post
hoc Tukey).
Celecoxib in combination with CT (30 μg 5FU/10 μg Oxali
+50 μM celecoxib) also significantly reduced the proliferation
signature when compared with CT alone (Figures 4b
and d; COX-2; 5FU/Oxali versus 5FU/Oxali+Celecoxib;
P=0.000242; β-Catenin; 5FU/Oxali versus 5FU/Oxali+
Celecoxib; P=0.00201; Ki-67; 5FU/Oxali versus 5FU/Oxali
+Celecoxib; P=0.021; ANOVA and post hoc Tukey). Aspirin in
combination with CT (30 μg 5FU/10 μg Oxali+2.5 mM Aspirin)
efficiently reduced expression of β-Catenin and Ki-67
(Figures 4c and d; β-Catenin; 5FU/Oxali versus 5FU/Oxali
+Aspirin; P=0.0003; Ki-67; 5FU/Oxali versus 5FU/Oxali
+Aspirin; P=0.003; ANOVA and post hoc Tukey). Aspirin
co-treatment did not significantly reduce expression of COX-2.
Figure 3 Caspase-3 is activated and apoptosis is induced following CT, and COX-2 inhibitors do not affect this process. (a) Fresh patient colon tumour tissue (N= 19
patients) was treated with 5FU-based CTalone and in combination with specific Caspase-3 inhibitor (DNLD) and COX-2 inhibitors (Aspirin and Celecoxib). Tissue was sectioned
and stained for ProCaspase-3 and active Caspase-3 (a) and scored based on extent and intensity of staining (scale bar= 100 μm). (b and c) Levels of ProCaspase-3 (b) and
active Caspase-3 (c) were quantified. ProCaspase-3 levels were unaffected by treatment regimes, while active Caspase-3 was significantly reduced (5FU/Oxali versus 5FU/Oxali
+DNLD, P= 0.021) by specific Caspase-3 inhibition alongside 5FU-based CT but unaffected by other treatments. (d) Using a TUNEL-based assay, levels of apoptosis were
examined. Chemotherapy-induced apoptosis (Untreated versus 5FU/Oxali, P= 0.00013), which was reduced with Caspase-3 inhibition (5FU/Oxali versus 5FU/Oxali+DNLD,
P= 0.001). COX-2 inhibition did not reduce apoptosis induction. *Denotes statistically significant difference, P-valuesp0.05.
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Epithelial mesenchymal transition (EMT) is a process that
occurs in several cancer types leading to increased motility
and invasiveness of cancer cells. Consequently, tumours with
high EMT often have a poor prognosis.22 The Zinc Finger
E-Box Binding Homeobox (ZEB) family of transcription factors
is integral to EMT.23 ZEB1 was previously shown to supress
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E-Cadherin expression via PGE2-mediated signalling.
24
Therefore, we investigated whether Caspase-3-driven prolif-
eration might impact EMT (Figure 4e). Explant samples were
examined for ZEB1 expression. Expression was not altered
across treatment groups, suggesting that the EMT does not
accompany Caspase-3-driven proliferation.
We finally performed double immunofluorescence staining
for active Caspase-3 and Ki-67 to obtain spatial information
regarding cell death versus cell proliferation in the same tissue
section. Semi-quantitative analysis of seven explant cultures
per treatment showed that the pattern reported in the
immunofluorescence staining was similar to that obtained by
immunohistochemistry (data not shown). Immunoreactivity
was present in both untreated and 5FU/Oxali-treated explant
cultures, with higher staining in 5FU/Oxali-treated cultures
(Figure 5a). Explant cultures treated with 5FU/Oxali+DLND
showed reduced levels of active Caspase-3 and Ki-67
(Figure 5a). Expression areas in 5FU/Oxali-treated cultures
did not show overlap, suggesting that the population of cells
with high proliferation differed from those with high caspase-3
activity. Active Caspase-3 staining was predominantly located
in the cytoplasm of epithelial cells of colonic crypts (Figure 5b).
Ki-67 nuclear staining corresponded to the zone of proliferat-
ing epithelial progenitors of the colonic crypts, where distinct
stem cell, proliferating, and differentiating compartments are
localised.25
Discussion
Executioner caspases such as Caspase-3 and Caspase-7
have long been recognised as the key proteases involved in
cellular degradation during apoptosis. Interestingly, in recent
years there is much evidence supporting a role for Caspase-3
in paracrine signalling, which may also influence signal
transduction and gene expression changes in neighbouring
cells that themselves did not activate caspases.6,26,27 Analysis
of TMAs of stage 2 and 3 CRC tumours revealed that low
levels of active Caspase-3 conferred a significant survival
advantage. We found that in patients receiving CT, active
Caspase-3 levels gave an even more notable survival
advantage, suggesting that while CT is activating Caspase-
3, high levels of the active protein may contribute to the
eventual relapse. In patients receiving CT, levels of low
ProCaspase-3 were suggestive of improved DFS for patients,
although not significant, implying that ProCaspase-3 levels
may be determinant of active Caspase-3 levels. In patients
who did not receive CT, Caspase-3 levels were not associated
with DFS, indicating that this phenomenon is present only
when CT is administered. This indicates that active Caspase-3
levels represent a potential predictive biomarker of patient
outcome and response to 5FU-based CT, helping to identify
individuals likely to respond to CT.
We also examined Caspase-3/-7 activity in the serum of 30
metastatic CRC patients. This analysis revealed that serum
Caspase-3/-7 activity was highest in patients with PD status,
and the poorest outlook, while those patients who respond to
therapy with either PD or SD have significantly lower levels of
activity. This indicated that circulating levels of active
Caspase-3/-7 influence disease progression and high levels
were similarly indicative of PD in the metastatic setting where
there is a higher tumour load. Cytokeratin 18 (CK18) is
cleaved by caspases during apoptosis and released into the
bloodstream.16,28 It has been recently reported that in the
serum of SCCHN patients levels of CK18 and cleaved
Caspase-3 were increased compared with that of normal
healthy controls. High CK18 levels and high Caspase-3
activity were also associated with shorter disease-free
progression in these patients.29 Taken together, these data
present evidence pointing to Caspase-3 as a potential
predictive biomarker of response to 5FU-based CT in
advanced CRC. Measurement of Caspase-3 in the tumour
or of Caspase-3/-7 activity in the serum may enable reliable
stratification of patients based on response and allow for the
identification of patients likely to respond poorly to 5FU-based
CT. However, analysis in larger cohorts and long-term studies
are required to further validate Caspase-3 or Caspase-3/-7
activity as a biomarker for early prediction of treatment
outcome or disease progression in CRC patients.
Because genotoxic therapy activates Caspase-3 to induce
tumour cell death, it may appear contradictory that low levels of
caspase-3 may be beneficial for responses to genotoxic CT.
However, colorectal tumours should be considered to be
highly heterogeneous with subpopulations of cells that vary in
their responses to CT. Moreover, each cycle of therapy may
only induce a fraction of tumour cells to undergo apoptosis
(‘fractional kill hypothesis’). Hence, fractional tumour killing
may induce caspase-dependent, compensatory cell prolifera-
tion in resistant cancer cells, leading to poor responsiveness to
treatment or early patient relapse. Tumour growth rates are
governed by the counterbalancing processes of cell prolifera-
tion and apoptosis. However the two events – Caspase-3
activation and cell proliferation – may occur at different time
Figure 4 Chemotherapy-induced Caspase-3 activation increases expression of proliferation markers, and inhibition of Caspase-3 and its downstream effectors antagonises
this proliferation signature. (a) Fresh patient colon tumour tissue was treated with 5FU-based CTalone and in combination with specific Caspase-3 inhibitor (DNLD) and COX-2
inhibitors (Aspirin and Celecoxib). Tissue was sectioned and stained for COX-2, β-Catenin, Ki-67, and ZEB1 (a) and scored based on the extent and intensity of staining (scale
bar= 100 μm). (b) COX-2 levels were significantly increased following CT when compared with untreated tissue (P= 0.00017). Expression of COX-2 was reduced when
Caspase-3 was inhibited during CT (P= 0.000443) and celecoxib co-treatment also significantly antagonised COX-2 expression (P= 0.000242). (c) CT significantly increased β-
Catenin levels when compared with untreated tissue (P= 0.00237). Specific Caspase-3 inhibition reduced β-Catenin expression significantly (P= 0.001), and inhibition of
downstream Caspase-3 effectors via aspirin and celecoxib resulted in reduction in β-Catenin expression (P= 0.0003 and P= 0.003, respectively). (d) Expression of Ki-67 was
not significantly increased following CTwhen compared with untreated tissue. Inhibition of Caspase-3 in concert with CT (P= 0.008) and its downstream effectors alongside 5FU-
based CT reduced Ki-67 expression (5FU/Oxali versus 5FU/Oxali+Celecoxib, P= 0.021, 5FU/Oxali versus 5FU/Oxali+Aspirin, P= 0.003). (e) Expression of ZEB1 was not
altered across treatment groups, suggesting that the EMT does not accompany Caspase-3-driven proliferation. (f) 5FU-based regimen caused a significant increase in PGE2
release (Untreated versus 5FU/Oxali, P= 0.034), while specific Caspase-3 and COX-2 inhibition reduced PGE2 media levels (5FU/Oxali versus 5FU/Oxali+DNLD, P= 0.033;
5FU/Oxali versus 5FU/Oxali+Aspirin, P= 0.021; 5FU/Oxali versus 5FU/Oxali+Celecoxib, P= 0.045; n= 4–6 explants evaluated per treatment; ANOVA and post hoc Tukey).
*Denotes statistically significant difference, P-valuesp0.05.
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points and at different time scales, and may not be detectable
in situ. Analysis of Ki-67 staining and active Caspase-3
staining on the CRC TMAs indicated a weak, positive
correlation in the CT group, but no correlation in the untreated
patient group, although none of these correlations were
statistically significant. Limitations of this approach were the
non-linearity of the scoring methodology and the fact that
tumour staining was scored before CT. We therefore explored
the relationship between Caspase-3 activation and cell
proliferation in more detail in the controlled environment of
tumour ex vivo cultures using a novel explant technique.17,18
Previous studies employing gelatine dental sponges found
that explant tumours retained tissue architecture and cellular-
ity comparable to that observed in the original tumour section
and retained similar expression of the key molecular
markers.17 Using this method, we could examine Caspase-3
activation and individual patient response to CT and,
furthermore, response to various antagonists alongside
traditional CT. Our results demonstrated that Caspase-3
activity induces cell proliferation in patient tumours. Specific
inhibition of Caspase-3 with Ac-DLND-CHO19 antagonised
this proliferation, as did selective COX-2 inhibition with
Celecoxib, suggesting that Caspase-3-dependent prolifera-
tion was mediated via COX-2. Double labelling of apoptosis
activation (active Caspase-3 staining) and cell proliferation
(Ki-67 staining) on CRC explant cultures demonstrated that
areas of active Caspase-3 and Ki-67 staining in tumour cells
did not overlap. Moreover, Ki-67 nuclear staining corre-
sponded to the zone of proliferating epithelial progenitors of
the colonic crypts, where distinct stem cell, proliferating, and
differentiating compartments are localised.25 Interestingly, we
also provide evidence that COX-2 levels were increased in
response to 5FU/Oxali therapy. It has been demonstrated that
COX-2 levels increase in a p53-dependent manner in
response to genotoxic therapy,30 although p53 has also been
shown to inhibit COX-2 gene induction.31 Our data suggest
that COX-2 induction in a largely intact tumour microenviron-
ment may also be Caspase-3 dependent, which adds further
insight into the regulation of PGE2 production and β-catenin
signalling during genotoxic stress in a more physiological
Figure 5 Active Caspase-3 and Ki-67 do not colocalise. (a) Tumour explant cultures remained untreated or were treated with 5FU/Oxali alone or in combination with the
specific Caspase-3 inhibitor, DNLD. Tissues were sectioned and double stained for immunofluorescence for active Caspase-3 (green, left panels) and Ki-67 (red, middle panels).
Nuclei were stained with Hoechst (blue, overlay in right panels). Represented images from n= x–y explant cultures per treatment condition are shown (scale bar= 50 μm).
(b) Detail of active Caspase-3 and Ki-67 staining in a 5FU/Oxaliplatin-treated culture, showing that Ki-67 nuclear staining corresponded to the zone of proliferating epithelial
progenitors of the colonic crypts, where distinct stem cell, proliferating, and differentiating compartments are localised (scale bar= 50 μm)
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setting. We also observed reduced COX-2 levels after
Celecoxib treatment. This is in agreement with the reported
positive feedback of prostaglandins including PGE2 on COX-2
induction.32,33
Caspase-3 inhibition in concert with 5FU-based CT may be
a viable approach for the treatment of advanced CRC. Clinical
phase I/II trials using pan-caspase inhibitors are currently
ongoing (http://ir.conatuspharma.com/releasedetail.cfm?
releaseid=908153). One caveat of this approach may be that
although specific caspase inhibition may impede tumour
repopulation, it may lack sufficient cell-death induction to
clear the initial tumour. However, genotoxic CT may activate
both caspase-dependent and -independent cell-death
pathways.34 Tumour growth in a lung cancer xenograft was
significantly delayed by Caspase-3 inhibition, and tumours
also displayed reduced vascularisation, highlighting the role of
Caspase-3 in tumour growth and progression.29 Nevertheless,
antagonising the repopulation pathway downstream of
Caspase-3 may offer a more attractive alternative, allowing
for cell-death induction but preventing proliferation signatures
from being activated. With this in mind, we utilised the COX-2
inhibitors, aspirin and celecoxib, in our studies. Both treat-
ments allowed for sufficient Caspase-3 activation, and
displayed apoptosis induction. However, upon analysis of
proliferation markers β-Catenin and Ki-67 we could demon-
strate that antagonising this Caspase-3-dependent pathway
at the COX-2 level reduced the expression of the proliferation
signature in tumour tissue. Interestingly, regular use of
aspirin after a diagnosis of CRC has been associated with a
superior clinical outcome.35 There is also evidence suggesting
that low daily doses of aspirin may be effective in reducing
colorectal cancer risk.36 Taken together, these results
suggest that COX-2 inhibitors may have potential as novel
co-treatments to compliment traditional chemotherapies in
advanced CRC.
Materials and Methods
TMA patient cohort. Patient tissue was collected and stored from the
Departments of Surgery and Pathology, Beaumont Hospital, Dublin, Ireland. To
ensure consistent quality and tumour presence, all tissues were microscopically
evaluated by an experienced pathologist. Only tumour samples containing over 50%
tumour cells were included in further analysis. Surgically resected colon tumour
tissue from patients (n= 93) was processed and formalin-fixed paraffin-embedded
(FFPE) for construction of TMAs. Clinical follow-up, including gender, age at
surgery, tumour grade, and adjuvant therapy regimes, was obtained through a
review of medical records by a dedicated clinical research nurse (Table 1). Patients
with hereditary forms of colorectal cancer were excluded. Informed consent was
obtained from all patients; and ethical approval was obtained by the Beaumont
Hospital Ethics Committee.
TMA construction. Three 1-mm cores were taken from every case where
available, using the Beecher Instruments arrayer (Sun Prairie, WI, USA) and placed
into a paraffin block. Arrays consisted of 90–100 cores per array. Sections 5 μm in
thickness were cut, floated onto adhesive slides and baked overnight at 65 °C.
Immunohistochemical staining. Antibodies were chosen based on their
suitability for use on FFPE tissue and optimised. All staining was performed on a
Leica Bond III automated immunostainer (Leica Microsystems, Wetzlar, Germany).
The following primary antibodies were used: ProCaspase-3 (1 : 200; Rabbit
polyclonal, HPA002643, Atlas Antibodies, Stockholm, Sweden), Active Caspase-3
(1:750; Rabbit polyclonal, 9661, CST, Cell Signaling Technology, Danvers, MA,
USA), COX-2 (1 : 400; Mouse monoclonal; CAY160112-1, Cayman (@Cambridge
Bioscience, Cambridge, UK)), and Ki-67 (MIB1) (1 : 100; Dako, Glostrup, Denmark,
M7240). Negative controls for both rabbit and mouse antibodies (Negative Control
Mouse Cocktail from mouse IgG1, IgG2a, IgG2b, IgG3, and IgM, IS750, Dako;
Negative Control Rabbit Immunoglobulin fraction of serum from non-immunized
rabbits, IS600, Dako) were included; and no staining was observed in these
controls. Visualisation was performed using the enhanced diaminobenzidine
tetrachloride with Harris′ haematoxylin as counterstain.
Immunohistochemical scoring. Following staining, cores were scored
based on the extent and intensity of the protein of interest. As multiple cores for
each patient were arrayed, mean intensity scores were used for all subsequent
analysis. Patients were allocated as those with either low or high protein levels,
based on whether the score was above or below the median. The specificity of
ProCaspase-3 and active Caspase-3 antibodies was confirmed by western blotting
using the HCT116 cell line+STS treatment. MCF7 cells were included as a negative
control.
Serological analysis patient cohort. Patients with metastasised
colorectal cancer (n= 30) received a standard CT based on 5FU, leukovorin (LV)
and oxaliplatin (FOLFOX) or 5FU, LV and irinotecan (FOLFIRI) +/− anti-EGFR or
anti-VEGF antibody application. Sera were collected at baseline (before therapy)
and day 14 of the first cycle of therapy and stored at − 20 °C. Therapy response
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was assessed according to the Response Evaluation Criteria in Solid Tumours
(RECIST) following the first cycle of therapy (Table 2). The study was conducted
according to the Ethics Committees of the National Centre for Tumour Diseases and
Hannover Medical School.
Serological detection of Caspase-3/-7 activity. For serological
measurement of Caspase-3/-7 activity, a luminescent substrate based assay was
used (Caspase-Glo assay, Promega, Mannheim, Germany) as described
previously.28
Explant culture medium and conditions. Collection media consists of
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen Corp, Carlsbad, CA, USA)
supplemented with penicillin (200 IU/l), streptomycin (200 μg/l), Fungizone (2.5 μg/
ml), ciprofloxacine (5 μg/ml), and gentamicin (125 μg/ml). Upon plating, all tissues
were cultured at 37 °C and 5% CO2 until harvest.
Dissection and plating of explant cultures. Under sterile conditions
and 2 h before tissue dissection, 1 cm3 haemostatic gelatine dental sponges
(Humanus Dental AB) were hydrated in 1 ml collection media at 37 °C in individual
wells of a 12-well cell-culture dish. Although sponges were hydrating, tissues were
transferred to a 10-cm cell-culture dish with 10 ml collection media for dissection.
Samples were then cut into 1 mm3 sections using a sterile scalpel blade. Sample
sections were washed in fresh collection media. Upon complete hydration of
gelatine sponges 1 mm3 dissected specimen sections were chosen at random and
placed on top of each sponge using sterile forceps. Explant cultures were incubated
at 37 °C and 5% CO2.
Treatments of explant cultures. All explants were maintained in collection
media for 24 h. At 24 h, media was aspirated carefully to prevent disturbance of
plated tissues, and 1 ml of treatment media was then added to the corresponding
treatment wells. Treatments were as follows: Untreated, 30 μg 5FU/10 μg Oxali,
30 μg 5FU/10 μg Oxali+200 nM DNLD, 30 μg 5FU/10 μg Oxali+2.5 mM Aspirin,
30 μg 5FU/10 μg Oxali+50 μM celecoxib. Tissues were treated for 96 h. At 96 h,
media was aspirated and stored at − 20 °C for prostaglandin E2 assay. Following
treatment, tissues were processed and FFPE for immunohistochemical analysis.
Immunohistochemical staining of explant cultures. In all, 5 μm
sections were cut using a microtome. Sections were floated onto slides and left to
air-dry. Sections were then baked overnight at 65 °C. Samples were deparaffinised
by passing through xylene and 100 and 70% ethanol washes. All staining was
performed using the DAKO EnVision+ System-HRP (DAB) kit for rabbit (K4010;
DAKO) or mouse (K4006; DAKO) primary antibodies. The following primary
antibodies were used: ProCaspase-3 (1 : 100; Rabbit polyclonal, HPA002643, Atlas
Antibodies), Active Caspase-3 (1 : 200; Rabbit polyclonal, 9661, CST), COX-2
(1 : 400; Mouse monoclonal; CAY160112-1, Cayman (@Cambridge Bioscience)),
β-Catenin (1 : 300; Neomarkers RB-9035 (Fisher Scientific, Fremont, CA, USA)),
Ki-67 (MIB1) (1 : 100; Dako, M7240), ZEB1 (1 : 100; Rabbit polyclonal, HPA027524,
Atlas Antibodies). Positive and negative controls were included according to the
suppliers′ recommendations (Negative Control Rabbit Immunoglobulin Fraction
(Normal), X 0903, Dako; Negative Control Mouse IgG1, X0931, Dako). Following
staining, sections were scored semi-quantitatively, on a scale of 0–3 based on the
extent and intensity of staining, as described above.
Double immunofluorescence staining of explant cultures. In all,
5 μm sections were baked, deparaffinised, and hydrated as previously described.
Specimens were washed using sodium citrate as antigen retrieval. Cells were
permeabilised for 30 min using 0.3% Triton X-100 in 1 × PBS. Sections were then
incubated overnight at 4 °C with Rabbit polyclonal Cleaved Caspase-3 Antibody
(1 : 200; 9661, Cell Signalling Technology) and Mouse Monoclonal Ki-67 Antibody
(MIB1. 1:50; Dako, M7240), diluted in 1 × PBS with 1% BSA and 0.3% Triton X-100.
Alexa Fluor 488 Donkey anti-Rabbit IgG (H+L) (A-21206, Life Technologies,
Carlsbad, CA, USA) and Alexa Fluor 568 Donkey anti-Mouse IgG (A-10037, Life
Technologies) secondary antibodies were used at 1:400 dilutions and incubated for
1 h at room temperature. Nuclei were counterstained with Hoechst stain solution.
Slides were mounted using DPX Slide mounting medium (06522, Sigma-Aldrich,
St. Louis, MO, USA). As a negative control to ensure specificity of staining, the
omission of the primary antibodies from the staining procedure was carried out on
some samples. Cells were imaged using a LSM 510 Meta (Carl Zeiss, Jena,
Germany) equipped with × 40 oil immersion objective using appropriate excitation,
beam splitter, and emission wavelength. Images were processed using ImageJ
(1.46r, Wayne Rasband, NIH, USA).
Apoptosis assay. To analyse apoptosis in each sample sections were
processed using the TdT-DAB in situ apoptosis detection kit (Trevigen, Gaithersburg,
MD, USA, 4810-30-K). Staining was carried out as per manufacturer’s instructions,
and stainings were scored once again based on the extent and intensity of DAB-
positive cells.
Prostaglandin E2 assay. To measure PGE2 levels according to the
treatment used; media was collected from the corresponding samples at 96 h of
treatment and was processed using the Prostaglandin E2 Parameter Assay Kit
(KGE004B, R&D Systems, St. Cloud, MN, USA). Optical density was determined
using a microplate reader set to 450 nm. Evaluation was carried out as per
manufacturer’s instructions. Standards and controls were included as described in
the kit.
Statistics. Statistical analyses were performed SPSS (IBM, Armonk, NY, USA).
Data are given as means±S.E.M. For statistical comparison, ANOVA and
subsequent Tukey test were used for normally distributed data. Relations between
levels of active Caspase-3 and Ki-67 on CRC TMAs were compared by Spearman
correlation test. Serum levels of activated Caspase-3 were compared by using
Mann–Whitney’s U test for non-normally distributed data. P-values≤ 0.05 were
considered statistically significant. ROC analyses were performed to calculate the
cutoff value of activated Caspase-3 in the serum that correctly predicts treatment
failure, that is, PD, at day 14 of CT.
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